Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

Teemu P. Miettinen, Julien Peltier, Anetta Härtlova, Marek Gierliński, Valerie M. Jansen, Matthias Trost (Lead / Corresponding author), Mikael Björklund (Lead / Corresponding author)

Research output: Contribution to journalArticle

28 Citations (Scopus)
240 Downloads (Pure)

Abstract

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib-induced senescence, we performed thermal proteome profiling of MCF7 breast cancer cells. In addition to affecting known CDK4/6 targets, palbociclib induces a thermal stabilization of the 20S proteasome, despite not directly binding to it. We further show that palbociclib treatment increases proteasome activity independently of the ubiquitin pathway. This leads to cellular senescence, which can be counteracted by proteasome inhibitors. Palbociclib-induced proteasome activation and senescence is mediated by reduced proteasomal association of ECM29. Loss of ECM29 activates the proteasome, blocks cell proliferation, and induces a senescence-like phenotype. Finally, we find that ECM29 mRNA levels are predictive of relapse-free survival in breast cancer patients treated with endocrine therapy. In conclusion, thermal proteome profiling identifies the proteasome and ECM29 protein as mediators of palbociclib activity in breast cancer cells.

Original languageEnglish
Article numbere98359
Pages (from-to)1-19
Number of pages19
JournalEMBO Journal
Volume37
Issue number10
Early online date18 Apr 2018
DOIs
Publication statusPublished - 15 May 2018

Keywords

  • breast cancer
  • CDK4
  • palbociclib
  • proteasome
  • thermal proteome profiling

Fingerprint Dive into the research topics of 'Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib'. Together they form a unique fingerprint.

  • Projects

    Cite this

    Miettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018). Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib. EMBO Journal, 37(10), 1-19. [e98359]. https://doi.org/10.15252/embj.201798359